5 Key Takeaways
-
1
The SPECTRA trial evaluated the safety and efficacy of 4D-150 for diabetic macular edema (DME).
-
2
The trial demonstrated that 4D-150 is extremely safe, with no intraocular inflammation events reported.
-
3
A significant dose response was observed, with a 9.7 letter increase in visual acuity at the high dose.
-
4
The treatment also resulted in a decrease in central subfield thickness, indicating improved retinal health.
-
5
4D-150 is delivered via intravitreal injection, making it a practical option for large-scale treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.